FRONTEO signs license agreement with Tokushima University clinical pharmacology field for paper search AI system

Home » corporate » News » 2020 » FRONTEO signs license agreement with Tokushima University clinical pharmacology field for paper search AI system
2020.09.30 Press release

--To the press -

FRONTEO signs license agreement with Tokushima University clinical pharmacology field for paper search AI system

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is a member of the Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Tokushima University (Tokushima City, Tokushima Prefecture, Professor: Keisuke Ishizawa). We have signed a license agreement for the use of the academic plan for educational and research institutions of the exploration AI system "Amanogawa".

 

"Amanogawa" is PubMedBy visualizing the detected information on a map with a system that can detect up to 3000 articles that are highly related to the entered word or sentence from the articles published in, in a short time of about 10 seconds. This is useful for greatly improving the efficiency of article search.

 

In educational / research institutes such as universities, there are many situations where it is necessary to search for treatises (eg, grasping the latest knowledge in specialized fields, researching peripheral information for research / writing papers, affiliated hospitals, etc.) Information for reference in diagnosis, treatment, and medication in Japan, reference to cases, etc.).In the field of clinical pharmacology, The University of Tokushima, which publishes numerous research results every year and has accumulated achievements, "Amanogawa" has been evaluated as a search tool that brings new research ideas and has been introduced.We believe that "Amanogawa" itself can grow significantly by being used by researchers and students who will lead the next generation.

 

* PubMed: A database that allows you to search for articles in the field of biomedical science. Created by NCBI (National Center for Biotechnology Information) in NLM (National Library of Medicine).

 

Amanogawaabout URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/

"Amanogawa (trademark / patent pending)" is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder ®, reading: concept encoder)".When a researcher inputs a sentence such as a word or hypothesis of interest, "Concept Encoder" instantly detects the article related to the input content from the large number of articles published in PubMed.

Since the search results are plotted in a map according to the similarity between the articles, you can check the relevance at a glance, and drag the article information detected on the map to narrow down the search, which is a visual that has never been seen before. You can search for articles.In addition, you can sort the search results in order of relevance and list their abstracts, greatly streamlining your article search.This makes it possible to discover events and new drug targets from a perspective that is difficult for humans to notice.

 

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO supports corporate business by extracting meaningful and important information from a huge amount of text data using the in-house developed AI engine "KIBIT®" and "concept encoder®" that specialize in natural language processing. It is a data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed. From 8, based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field, and use AI to "turn text data into knowledge" to support drug discovery. We contribute to solving various corporate issues such as dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

 

<Contact information for the press>

FRONTEO Inc.
Public Relations Segawa / Murayama
Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact